Back to search results

Bimatoprost Implant System with SpyGlass IOL for Glaucoma and Cataracts

This study is looking at a new way to treat mild to moderate open-angle glaucoma or ocular hypertension (high pressure in the eye) in people who are also having cataract surgery. It compares the Bimatoprost Implant System combined with the SpyGlass IOL (an intraocular lens used during cataract surgery) to Timolol Ophthalmic Solution (eye drops). The main goals are to see how much eye pressure is reduced and if your vision improves to 20/40 or better. You might be able to join if you have these conditions and are having cataract surgery. The study plans to enroll 400 participants, but its current status is unclear.

Study design
This is a randomized study, meaning participants are assigned by chance to receive one of the treatments. It plans to enroll 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your eye pressure will be measured at 2 and 6 weeks, and at 3 months. Your vision will be checked at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07218796

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Recruiting
PHASE3Ages 22+InterventionalTreatment
SpyGlass Pharma, Inc.
~400 participants
Updated 2025-10-20 on ClinicalTrials.gov
What's tested:Bimatoprost Implant SystemSpyGlass IOLTimolol Maleate Ophthalmic Solution, 0.5%Commercial IOL

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean IOP Reduction from Baseline (mmHg)
Measured over Weeks 2 and 6, and Month 3
+1 more outcome measured

Conditions

Cataract
Glaucoma
Ocular Hypertension

Explore related trials

CataractGlaucomaOcular Hypertension

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Paul Yoo, OD · STUDY_CHAIR · SpyGlass Pharma

Who to contact

Director, Clinical Affairs
[email protected]
949-284-6904
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension
Planned removal of cataract
Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception

Exclusion

Uncontrolled systemic disease
History of incisional/refractive corneal surgery
Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma
History of incisional glaucoma surgery or intraocular injections
Other ocular diseases, pathology, or conditions

What this trial measures

  • Mean IOP Reduction from Baseline (mmHg)Weeks 2 and 6, and Month 3

    Time-matched mean IOP change from Baseline in the study eyes at all the individual IOP timepoints

  • BCDVA 20/40 or betterMonth 6

    Study eyes achieving best corrected distance visual acuity (BCDVA) of 20/40 or better